| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Community Health Centers | 13 | 2024 | 117 | 2.330 |
Why?
|
| Diabetes Mellitus | 22 | 2024 | 744 | 2.320 |
Why?
|
| Endocrine Disruptors | 6 | 2009 | 28 | 1.440 |
Why?
|
| Coturnix | 8 | 2009 | 13 | 1.410 |
Why?
|
| Genital Neoplasms, Female | 6 | 2017 | 108 | 1.300 |
Why?
|
| Islam | 3 | 2019 | 34 | 1.300 |
Why?
|
| Melanoma | 14 | 2015 | 471 | 1.020 |
Why?
|
| Mammography | 3 | 2019 | 475 | 0.970 |
Why?
|
| Diabetes Mellitus, Type 2 | 15 | 2024 | 1181 | 0.960 |
Why?
|
| Reproduction | 4 | 2009 | 199 | 0.920 |
Why?
|
| Skin Neoplasms | 14 | 2015 | 598 | 0.900 |
Why?
|
| Bursa of Fabricius | 3 | 2009 | 4 | 0.870 |
Why?
|
| Dichlorodiphenyl Dichloroethylene | 4 | 2007 | 6 | 0.830 |
Why?
|
| Trenbolone Acetate | 3 | 2007 | 3 | 0.810 |
Why?
|
| Patient-Centered Care | 7 | 2014 | 211 | 0.810 |
Why?
|
| Health Behavior | 6 | 2018 | 185 | 0.800 |
Why?
|
| Female | 103 | 2024 | 46635 | 0.790 |
Why?
|
| Office Visits | 1 | 2022 | 50 | 0.770 |
Why?
|
| Patient Outcome Assessment | 1 | 2022 | 84 | 0.760 |
Why?
|
| Colinus | 4 | 2009 | 4 | 0.750 |
Why?
|
| Self Care | 9 | 2023 | 166 | 0.730 |
Why?
|
| Abortion, Induced | 4 | 2019 | 140 | 0.720 |
Why?
|
| Social Support | 7 | 2024 | 216 | 0.690 |
Why?
|
| Middle Aged | 68 | 2024 | 26191 | 0.670 |
Why?
|
| Primary Health Care | 6 | 2022 | 352 | 0.670 |
Why?
|
| Patient Education as Topic | 13 | 2019 | 365 | 0.640 |
Why?
|
| Sexual Behavior, Animal | 3 | 2009 | 95 | 0.630 |
Why?
|
| Healthcare Disparities | 7 | 2015 | 432 | 0.630 |
Why?
|
| Humans | 123 | 2024 | 90039 | 0.630 |
Why?
|
| Adult | 63 | 2024 | 26856 | 0.630 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2023 | 262 | 0.610 |
Why?
|
| Attitude of Health Personnel | 8 | 2022 | 654 | 0.590 |
Why?
|
| Intention | 2 | 2016 | 51 | 0.590 |
Why?
|
| Aged | 49 | 2024 | 19280 | 0.580 |
Why?
|
| Soil Pollutants | 4 | 2010 | 7 | 0.580 |
Why?
|
| Mexican Americans | 3 | 2023 | 67 | 0.570 |
Why?
|
| Sexual Maturation | 2 | 2007 | 35 | 0.560 |
Why?
|
| Denervation | 1 | 2016 | 25 | 0.560 |
Why?
|
| Environmental Pollutants | 5 | 2012 | 52 | 0.550 |
Why?
|
| Arabs | 1 | 2016 | 16 | 0.540 |
Why?
|
| Health Services Accessibility | 7 | 2021 | 438 | 0.540 |
Why?
|
| Patient Participation | 6 | 2012 | 226 | 0.530 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2008 | 297 | 0.520 |
Why?
|
| Male | 74 | 2024 | 42721 | 0.520 |
Why?
|
| Breast Neoplasms | 5 | 2016 | 3022 | 0.510 |
Why?
|
| Decision Making | 5 | 2012 | 671 | 0.510 |
Why?
|
| Placenta | 1 | 2016 | 181 | 0.490 |
Why?
|
| Pregnancy, Tubal | 1 | 2014 | 4 | 0.480 |
Why?
|
| Androgen Antagonists | 2 | 2006 | 138 | 0.470 |
Why?
|
| Attitude to Health | 5 | 2016 | 222 | 0.460 |
Why?
|
| Triazines | 3 | 2009 | 54 | 0.460 |
Why?
|
| Fallopian Tubes | 1 | 2014 | 46 | 0.460 |
Why?
|
| Sentinel Lymph Node Biopsy | 6 | 2014 | 73 | 0.460 |
Why?
|
| Interviews as Topic | 11 | 2023 | 344 | 0.450 |
Why?
|
| Explosive Agents | 3 | 2009 | 4 | 0.440 |
Why?
|
| Delivery of Health Care, Integrated | 3 | 2021 | 59 | 0.440 |
Why?
|
| Toxicity Tests | 3 | 2010 | 13 | 0.430 |
Why?
|
| Lymph Node Excision | 6 | 2017 | 221 | 0.430 |
Why?
|
| Ovarian Neoplasms | 4 | 2017 | 772 | 0.410 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2014 | 157 | 0.410 |
Why?
|
| Surveys and Questionnaires | 14 | 2019 | 2658 | 0.400 |
Why?
|
| Physician-Patient Relations | 9 | 2016 | 625 | 0.400 |
Why?
|
| Health Promotion | 3 | 2019 | 165 | 0.390 |
Why?
|
| Midwestern United States | 7 | 2024 | 83 | 0.390 |
Why?
|
| Depression | 3 | 2022 | 513 | 0.380 |
Why?
|
| Family | 4 | 2023 | 324 | 0.380 |
Why?
|
| Self-Management | 2 | 2023 | 42 | 0.380 |
Why?
|
| Safety-net Providers | 3 | 2017 | 37 | 0.380 |
Why?
|
| Gonads | 2 | 2009 | 19 | 0.380 |
Why?
|
| Health Care Surveys | 5 | 2019 | 281 | 0.370 |
Why?
|
| Dinitrobenzenes | 2 | 2007 | 5 | 0.370 |
Why?
|
| Physicians | 6 | 2019 | 692 | 0.370 |
Why?
|
| Quality Assurance, Health Care | 5 | 2012 | 225 | 0.360 |
Why?
|
| Psychiatry | 2 | 2022 | 82 | 0.360 |
Why?
|
| Anxiety | 1 | 2013 | 311 | 0.360 |
Why?
|
| Mass Screening | 7 | 2016 | 649 | 0.350 |
Why?
|
| United States | 17 | 2023 | 7116 | 0.350 |
Why?
|
| Embryo, Nonmammalian | 4 | 2007 | 196 | 0.350 |
Why?
|
| Burnout, Professional | 2 | 2012 | 102 | 0.350 |
Why?
|
| Focus Groups | 7 | 2023 | 177 | 0.350 |
Why?
|
| Pregnancy | 8 | 2019 | 3042 | 0.350 |
Why?
|
| Health Knowledge, Attitudes, Practice | 6 | 2024 | 540 | 0.350 |
Why?
|
| Psychometrics | 4 | 2019 | 330 | 0.340 |
Why?
|
| Religion | 4 | 2018 | 88 | 0.330 |
Why?
|
| Environmental Exposure | 6 | 2012 | 334 | 0.330 |
Why?
|
| Pentaerythritol Tetranitrate | 1 | 2009 | 1 | 0.330 |
Why?
|
| Morale | 2 | 2012 | 16 | 0.330 |
Why?
|
| Hypothalamus | 1 | 2009 | 79 | 0.320 |
Why?
|
| Fetal Development | 1 | 2009 | 31 | 0.320 |
Why?
|
| Adolescent | 31 | 2019 | 9355 | 0.320 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2009 | 106 | 0.310 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2015 | 1355 | 0.310 |
Why?
|
| Adenocarcinoma | 2 | 2007 | 1185 | 0.300 |
Why?
|
| Vasodilator Agents | 1 | 2009 | 145 | 0.300 |
Why?
|
| Australia | 7 | 2017 | 101 | 0.300 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2012 | 1929 | 0.300 |
Why?
|
| Personnel Management | 1 | 2008 | 7 | 0.300 |
Why?
|
| Carcinoma | 3 | 2008 | 438 | 0.300 |
Why?
|
| Estradiol | 1 | 2009 | 250 | 0.300 |
Why?
|
| Copulation | 1 | 2007 | 5 | 0.300 |
Why?
|
| Water Pollutants, Chemical | 1 | 2009 | 135 | 0.300 |
Why?
|
| Depressive Disorder | 2 | 2013 | 221 | 0.290 |
Why?
|
| Models, Animal | 1 | 2009 | 277 | 0.290 |
Why?
|
| Patient Care Team | 2 | 2014 | 284 | 0.290 |
Why?
|
| Community Health Services | 3 | 2014 | 81 | 0.290 |
Why?
|
| Biomarkers, Tumor | 3 | 2005 | 1545 | 0.290 |
Why?
|
| Anabolic Agents | 1 | 2007 | 3 | 0.280 |
Why?
|
| Spirituality | 2 | 2013 | 87 | 0.280 |
Why?
|
| Patient Protection and Affordable Care Act | 2 | 2019 | 67 | 0.280 |
Why?
|
| Occupational Health Services | 1 | 2006 | 4 | 0.280 |
Why?
|
| Endometrial Neoplasms | 3 | 2014 | 208 | 0.270 |
Why?
|
| Contraception | 3 | 2019 | 93 | 0.270 |
Why?
|
| Adaptation, Psychological | 3 | 2019 | 166 | 0.270 |
Why?
|
| Chicago | 15 | 2018 | 1434 | 0.270 |
Why?
|
| Aged, 80 and over | 21 | 2015 | 6790 | 0.270 |
Why?
|
| Lymphatic Metastasis | 8 | 2014 | 496 | 0.270 |
Why?
|
| Educational Status | 3 | 2013 | 195 | 0.270 |
Why?
|
| Medicaid | 2 | 2020 | 242 | 0.270 |
Why?
|
| Workplace | 1 | 2006 | 30 | 0.270 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2007 | 159 | 0.260 |
Why?
|
| Immunity, Cellular | 1 | 2007 | 178 | 0.260 |
Why?
|
| Qualitative Research | 6 | 2023 | 306 | 0.260 |
Why?
|
| Animals | 22 | 2012 | 27543 | 0.260 |
Why?
|
| Trinitrotoluene | 3 | 2012 | 3 | 0.260 |
Why?
|
| Pilot Projects | 7 | 2022 | 872 | 0.260 |
Why?
|
| Health Education | 1 | 2006 | 105 | 0.260 |
Why?
|
| Motivational Interviewing | 2 | 2016 | 21 | 0.260 |
Why?
|
| Neoplasm Staging | 9 | 2015 | 2001 | 0.250 |
Why?
|
| Lymph Nodes | 5 | 2014 | 550 | 0.250 |
Why?
|
| Mortality | 2 | 2003 | 149 | 0.250 |
Why?
|
| Complementary Therapies | 1 | 2006 | 56 | 0.250 |
Why?
|
| Program Evaluation | 6 | 2014 | 311 | 0.250 |
Why?
|
| Language | 2 | 2019 | 157 | 0.250 |
Why?
|
| Papillomavirus Infections | 1 | 2008 | 264 | 0.250 |
Why?
|
| Religion and Medicine | 3 | 2016 | 122 | 0.240 |
Why?
|
| Occupations | 1 | 2005 | 25 | 0.240 |
Why?
|
| Emigration and Immigration | 1 | 2005 | 48 | 0.240 |
Why?
|
| Early Detection of Cancer | 3 | 2018 | 423 | 0.240 |
Why?
|
| Dermatologic Surgical Procedures | 2 | 2014 | 16 | 0.240 |
Why?
|
| Models, Theoretical | 2 | 2007 | 493 | 0.240 |
Why?
|
| Quality Improvement | 5 | 2016 | 457 | 0.240 |
Why?
|
| Lymphedema | 2 | 2017 | 77 | 0.230 |
Why?
|
| Cross-Sectional Studies | 9 | 2022 | 1731 | 0.230 |
Why?
|
| Health Personnel | 3 | 2017 | 214 | 0.230 |
Why?
|
| Weight Loss | 4 | 2006 | 233 | 0.230 |
Why?
|
| Catholicism | 2 | 2015 | 43 | 0.230 |
Why?
|
| Morphogenesis | 1 | 2005 | 207 | 0.230 |
Why?
|
| Lizards | 4 | 2012 | 25 | 0.220 |
Why?
|
| Lead | 3 | 2010 | 28 | 0.220 |
Why?
|
| Ascitic Fluid | 1 | 2003 | 38 | 0.220 |
Why?
|
| Patient Preference | 2 | 2016 | 112 | 0.220 |
Why?
|
| Obesity | 6 | 2013 | 972 | 0.220 |
Why?
|
| Frail Elderly | 1 | 2024 | 80 | 0.220 |
Why?
|
| Allied Health Personnel | 2 | 2001 | 20 | 0.210 |
Why?
|
| Body Weight | 6 | 2010 | 453 | 0.200 |
Why?
|
| Frailty | 1 | 2024 | 79 | 0.200 |
Why?
|
| Follow-Up Studies | 11 | 2015 | 3684 | 0.200 |
Why?
|
| Tumor Cells, Cultured | 1 | 2003 | 1048 | 0.190 |
Why?
|
| Tissue and Organ Procurement | 1 | 2006 | 362 | 0.190 |
Why?
|
| Community-Based Participatory Research | 2 | 2019 | 37 | 0.190 |
Why?
|
| Overweight | 3 | 2011 | 119 | 0.190 |
Why?
|
| Mental Health Services | 1 | 2021 | 59 | 0.190 |
Why?
|
| Neoplasms | 4 | 2008 | 3067 | 0.180 |
Why?
|
| Young Adult | 14 | 2016 | 6427 | 0.180 |
Why?
|
| Behavior Therapy | 2 | 2011 | 88 | 0.180 |
Why?
|
| Rural Health Services | 2 | 2014 | 17 | 0.180 |
Why?
|
| Delivery of Health Care | 3 | 2023 | 437 | 0.180 |
Why?
|
| Financing, Organized | 1 | 2020 | 12 | 0.180 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 197 | 0.180 |
Why?
|
| Child | 19 | 2019 | 7244 | 0.180 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2020 | 24 | 0.170 |
Why?
|
| Health Services Needs and Demand | 2 | 2019 | 108 | 0.170 |
Why?
|
| Social Class | 8 | 2013 | 137 | 0.170 |
Why?
|
| Insurance Coverage | 3 | 2019 | 127 | 0.170 |
Why?
|
| Organ Size | 4 | 2012 | 372 | 0.170 |
Why?
|
| Respite Care | 1 | 2019 | 9 | 0.170 |
Why?
|
| Prejudice | 2 | 2010 | 48 | 0.170 |
Why?
|
| Equipment and Supplies | 1 | 2019 | 28 | 0.170 |
Why?
|
| State Health Plans | 1 | 2019 | 14 | 0.170 |
Why?
|
| Patient Satisfaction | 2 | 2016 | 462 | 0.160 |
Why?
|
| Job Satisfaction | 2 | 2012 | 79 | 0.160 |
Why?
|
| Disabled Children | 1 | 2019 | 44 | 0.160 |
Why?
|
| Reproducibility of Results | 4 | 2019 | 2770 | 0.160 |
Why?
|
| Blood Glucose | 2 | 2021 | 837 | 0.160 |
Why?
|
| Time Factors | 8 | 2017 | 5362 | 0.160 |
Why?
|
| Survival Rate | 9 | 2015 | 1901 | 0.160 |
Why?
|
| Vulvar Neoplasms | 2 | 2017 | 20 | 0.160 |
Why?
|
| Self Concept | 1 | 2019 | 135 | 0.150 |
Why?
|
| Aftercare | 1 | 2019 | 88 | 0.150 |
Why?
|
| Insecticides | 3 | 2007 | 27 | 0.150 |
Why?
|
| Vaginal Neoplasms | 2 | 2017 | 84 | 0.150 |
Why?
|
| Clinical Decision-Making | 2 | 2019 | 281 | 0.150 |
Why?
|
| Spleen | 3 | 2009 | 433 | 0.150 |
Why?
|
| Prospective Studies | 10 | 2023 | 4326 | 0.150 |
Why?
|
| Continuity of Patient Care | 2 | 2017 | 172 | 0.140 |
Why?
|
| Internet | 2 | 2012 | 323 | 0.140 |
Why?
|
| Exercise | 5 | 2024 | 328 | 0.140 |
Why?
|
| Leukocytes | 3 | 2010 | 209 | 0.140 |
Why?
|
| Ovum | 2 | 2007 | 59 | 0.140 |
Why?
|
| Prognosis | 9 | 2015 | 3801 | 0.140 |
Why?
|
| Rare Diseases | 1 | 2017 | 69 | 0.140 |
Why?
|
| Forecasting | 6 | 2008 | 304 | 0.140 |
Why?
|
| Risk Factors | 8 | 2017 | 5567 | 0.140 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2017 | 75 | 0.140 |
Why?
|
| Professional-Patient Relations | 2 | 2014 | 54 | 0.130 |
Why?
|
| Public Health Surveillance | 1 | 2016 | 22 | 0.130 |
Why?
|
| Cardiovascular System | 1 | 2016 | 63 | 0.130 |
Why?
|
| Chronic Disease | 3 | 2016 | 960 | 0.130 |
Why?
|
| Hepatitis B, Chronic | 1 | 2016 | 32 | 0.130 |
Why?
|
| Referral and Consultation | 3 | 2006 | 345 | 0.130 |
Why?
|
| Feasibility Studies | 5 | 2019 | 785 | 0.130 |
Why?
|
| Quality of Health Care | 2 | 2011 | 387 | 0.130 |
Why?
|
| Child, Preschool | 10 | 2019 | 3774 | 0.130 |
Why?
|
| Parents | 2 | 2010 | 290 | 0.130 |
Why?
|
| Syndrome | 1 | 2016 | 450 | 0.130 |
Why?
|
| Substance-Related Disorders | 1 | 2020 | 422 | 0.130 |
Why?
|
| Victoria | 2 | 2006 | 5 | 0.130 |
Why?
|
| Brain Neoplasms | 2 | 2014 | 784 | 0.130 |
Why?
|
| Models, Organizational | 2 | 2013 | 48 | 0.130 |
Why?
|
| Hypoglycemic Agents | 2 | 2016 | 352 | 0.130 |
Why?
|
| Early Medical Intervention | 1 | 2015 | 20 | 0.120 |
Why?
|
| Incidence | 6 | 2017 | 1604 | 0.120 |
Why?
|
| Administration, Oral | 4 | 2009 | 667 | 0.120 |
Why?
|
| Health Status | 2 | 2014 | 371 | 0.120 |
Why?
|
| Wales | 7 | 2008 | 9 | 0.120 |
Why?
|
| Program Development | 3 | 2014 | 127 | 0.120 |
Why?
|
| Medication Adherence | 1 | 2016 | 139 | 0.120 |
Why?
|
| England | 7 | 2008 | 38 | 0.120 |
Why?
|
| Practice Management, Medical | 1 | 2014 | 23 | 0.120 |
Why?
|
| Feedback | 1 | 2015 | 134 | 0.120 |
Why?
|
| Gynecology | 1 | 2016 | 129 | 0.120 |
Why?
|
| Counseling | 1 | 2016 | 166 | 0.120 |
Why?
|
| Cultural Competency | 1 | 2014 | 21 | 0.120 |
Why?
|
| Diet | 3 | 2012 | 444 | 0.110 |
Why?
|
| Scalp | 1 | 2014 | 72 | 0.110 |
Why?
|
| Edema | 1 | 2014 | 70 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 3 | 2015 | 569 | 0.110 |
Why?
|
| Age Factors | 5 | 2007 | 1880 | 0.110 |
Why?
|
| DNA Mismatch Repair | 1 | 2013 | 58 | 0.110 |
Why?
|
| Hutchinson's Melanotic Freckle | 1 | 2013 | 4 | 0.110 |
Why?
|
| Dermoscopy | 1 | 2013 | 6 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 2012 | 566 | 0.110 |
Why?
|
| Physicians, Primary Care | 1 | 2015 | 105 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2015 | 608 | 0.110 |
Why?
|
| Patient Handoff | 1 | 2015 | 95 | 0.110 |
Why?
|
| Environmental Monitoring | 2 | 2012 | 81 | 0.110 |
Why?
|
| Disease Management | 3 | 2014 | 328 | 0.110 |
Why?
|
| Personnel Turnover | 1 | 2013 | 9 | 0.110 |
Why?
|
| No-Observed-Adverse-Effect Level | 2 | 2010 | 2 | 0.110 |
Why?
|
| Malaria | 1 | 2012 | 23 | 0.100 |
Why?
|
| Europe | 2 | 2003 | 324 | 0.100 |
Why?
|
| Microscopy, Confocal | 1 | 2013 | 280 | 0.100 |
Why?
|
| Medical Oncology | 1 | 2016 | 384 | 0.100 |
Why?
|
| Blotting, Western | 2 | 2004 | 793 | 0.100 |
Why?
|
| Life Style | 3 | 2016 | 176 | 0.100 |
Why?
|
| Standard of Care | 1 | 2012 | 65 | 0.100 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2013 | 313 | 0.100 |
Why?
|
| Trust | 1 | 2012 | 97 | 0.100 |
Why?
|
| Depressive Disorder, Major | 1 | 2013 | 167 | 0.100 |
Why?
|
| Urodela | 2 | 2009 | 19 | 0.100 |
Why?
|
| Peer Group | 1 | 2012 | 86 | 0.100 |
Why?
|
| Infant | 7 | 2019 | 3190 | 0.100 |
Why?
|
| Professional Role | 2 | 2011 | 41 | 0.090 |
Why?
|
| Prevalence | 3 | 2017 | 1250 | 0.090 |
Why?
|
| Quality of Life | 2 | 2023 | 1682 | 0.090 |
Why?
|
| Urban Health Services | 2 | 2010 | 44 | 0.090 |
Why?
|
| Residence Characteristics | 4 | 2007 | 203 | 0.090 |
Why?
|
| Diet, Reducing | 2 | 2006 | 29 | 0.090 |
Why?
|
| Disease Progression | 2 | 2013 | 1469 | 0.090 |
Why?
|
| Germ-Line Mutation | 1 | 2013 | 347 | 0.090 |
Why?
|
| Hypertension | 1 | 2016 | 747 | 0.090 |
Why?
|
| Family Health | 1 | 2011 | 162 | 0.090 |
Why?
|
| Child Health Services | 1 | 2011 | 49 | 0.090 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2017 | 48 | 0.090 |
Why?
|
| Urban Population | 5 | 2007 | 224 | 0.090 |
Why?
|
| Emergency Service, Hospital | 1 | 2015 | 530 | 0.090 |
Why?
|
| Adenocarcinoma, Clear Cell | 2 | 2017 | 61 | 0.090 |
Why?
|
| Schools | 1 | 2011 | 77 | 0.090 |
Why?
|
| Coronary Disease | 1 | 1991 | 260 | 0.090 |
Why?
|
| Ambulatory Care Facilities | 1 | 2011 | 111 | 0.090 |
Why?
|
| Clinical Trials as Topic | 2 | 2013 | 1134 | 0.090 |
Why?
|
| Azocines | 1 | 2009 | 3 | 0.090 |
Why?
|
| Firearms | 2 | 2010 | 69 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 2 | 2016 | 1055 | 0.090 |
Why?
|
| Immunohistochemistry | 4 | 2013 | 1801 | 0.090 |
Why?
|
| Leukocyte Count | 2 | 2010 | 224 | 0.080 |
Why?
|
| General Surgery | 1 | 2012 | 236 | 0.080 |
Why?
|
| 1-Octanol | 1 | 2009 | 1 | 0.080 |
Why?
|
| Antineoplastic Agents | 2 | 2017 | 2331 | 0.080 |
Why?
|
| Body Weights and Measures | 1 | 2009 | 27 | 0.080 |
Why?
|
| Biodegradation, Environmental | 1 | 2009 | 18 | 0.080 |
Why?
|
| Nuclear Proteins | 1 | 2013 | 728 | 0.080 |
Why?
|
| Sex Ratio | 1 | 2009 | 23 | 0.080 |
Why?
|
| Tissue Distribution | 1 | 2009 | 293 | 0.080 |
Why?
|
| Chi-Square Distribution | 2 | 2014 | 359 | 0.080 |
Why?
|
| DNA Methylation | 1 | 2013 | 666 | 0.080 |
Why?
|
| Vietnam | 1 | 2008 | 14 | 0.080 |
Why?
|
| Malaysia | 1 | 2008 | 12 | 0.080 |
Why?
|
| Indonesia | 1 | 2008 | 11 | 0.080 |
Why?
|
| Wrist Joint | 1 | 2008 | 24 | 0.080 |
Why?
|
| Philippines | 1 | 2008 | 22 | 0.080 |
Why?
|
| Human papillomavirus 18 | 1 | 2008 | 16 | 0.080 |
Why?
|
| Thailand | 1 | 2008 | 57 | 0.080 |
Why?
|
| Papanicolaou Test | 1 | 2008 | 39 | 0.080 |
Why?
|
| Human papillomavirus 16 | 1 | 2008 | 38 | 0.080 |
Why?
|
| Mercury | 1 | 1988 | 12 | 0.080 |
Why?
|
| Employee Incentive Plans | 1 | 2008 | 4 | 0.080 |
Why?
|
| Personnel Loyalty | 1 | 2008 | 4 | 0.080 |
Why?
|
| Health Facility Administrators | 1 | 2008 | 15 | 0.080 |
Why?
|
| Solubility | 1 | 2009 | 185 | 0.080 |
Why?
|
| Vaginal Smears | 1 | 2008 | 71 | 0.080 |
Why?
|
| Toluene | 1 | 2008 | 5 | 0.080 |
Why?
|
| Antirheumatic Agents | 1 | 2008 | 58 | 0.080 |
Why?
|
| Pregnancy, Unplanned | 2 | 2019 | 18 | 0.080 |
Why?
|
| Survival Analysis | 5 | 2008 | 1497 | 0.080 |
Why?
|
| Case-Control Studies | 4 | 2015 | 1869 | 0.080 |
Why?
|
| Nail Diseases | 1 | 2007 | 6 | 0.070 |
Why?
|
| Laryngeal Neoplasms | 1 | 2008 | 89 | 0.070 |
Why?
|
| Professional Autonomy | 1 | 2008 | 41 | 0.070 |
Why?
|
| Longitudinal Studies | 4 | 2017 | 1081 | 0.070 |
Why?
|
| Sex Differentiation | 1 | 2007 | 9 | 0.070 |
Why?
|
| CA-125 Antigen | 2 | 2005 | 22 | 0.070 |
Why?
|
| Eggs | 1 | 2007 | 12 | 0.070 |
Why?
|
| Sociology, Medical | 1 | 2007 | 4 | 0.070 |
Why?
|
| Staff Development | 1 | 2008 | 27 | 0.070 |
Why?
|
| Papillomavirus Vaccines | 1 | 2008 | 58 | 0.070 |
Why?
|
| Endocrine System | 1 | 2007 | 17 | 0.070 |
Why?
|
| Body Mass Index | 4 | 2017 | 776 | 0.070 |
Why?
|
| Patient Care Management | 1 | 2007 | 30 | 0.070 |
Why?
|
| Fertility | 1 | 2007 | 116 | 0.070 |
Why?
|
| Head and Neck Neoplasms | 1 | 2014 | 1061 | 0.070 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2008 | 171 | 0.070 |
Why?
|
| Birds | 2 | 2007 | 166 | 0.070 |
Why?
|
| Psychology, Educational | 1 | 2006 | 2 | 0.070 |
Why?
|
| Workload | 1 | 2008 | 129 | 0.070 |
Why?
|
| United Kingdom | 2 | 2003 | 165 | 0.070 |
Why?
|
| Disease-Free Survival | 3 | 2014 | 1170 | 0.070 |
Why?
|
| Teaching Materials | 1 | 2006 | 14 | 0.070 |
Why?
|
| Retrospective Studies | 5 | 2014 | 9246 | 0.070 |
Why?
|
| Electronic Mail | 1 | 2006 | 15 | 0.070 |
Why?
|
| Postoperative Complications | 1 | 2017 | 2317 | 0.070 |
Why?
|
| Central Nervous System | 1 | 2007 | 153 | 0.070 |
Why?
|
| Models, Educational | 1 | 2006 | 49 | 0.070 |
Why?
|
| Vaccination | 1 | 2008 | 279 | 0.070 |
Why?
|
| Cohort Studies | 4 | 2014 | 2889 | 0.070 |
Why?
|
| Immunocompetence | 1 | 2006 | 26 | 0.070 |
Why?
|
| Embryonic Development | 1 | 2006 | 79 | 0.060 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2009 | 1237 | 0.060 |
Why?
|
| DDT | 1 | 2005 | 4 | 0.060 |
Why?
|
| Glioma | 1 | 2008 | 295 | 0.060 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2008 | 346 | 0.060 |
Why?
|
| Documentation | 1 | 2006 | 103 | 0.060 |
Why?
|
| Skeleton | 1 | 2005 | 27 | 0.060 |
Why?
|
| Sexual Behavior | 1 | 2008 | 314 | 0.060 |
Why?
|
| Models, Psychological | 1 | 2006 | 158 | 0.060 |
Why?
|
| Logistic Models | 3 | 2019 | 1214 | 0.060 |
Why?
|
| Emigrants and Immigrants | 2 | 2016 | 43 | 0.060 |
Why?
|
| Endocrine Glands | 1 | 2005 | 13 | 0.060 |
Why?
|
| Demography | 1 | 2006 | 183 | 0.060 |
Why?
|
| Fear | 1 | 2006 | 79 | 0.060 |
Why?
|
| Lethal Dose 50 | 3 | 2009 | 8 | 0.060 |
Why?
|
| Blood Proteins | 1 | 2005 | 149 | 0.060 |
Why?
|
| Primary Prevention | 1 | 2006 | 82 | 0.060 |
Why?
|
| Marital Status | 1 | 2005 | 42 | 0.060 |
Why?
|
| Registries | 3 | 2008 | 809 | 0.060 |
Why?
|
| Adaptation, Physiological | 1 | 2007 | 317 | 0.060 |
Why?
|
| Mexico | 1 | 2005 | 70 | 0.060 |
Why?
|
| Oregon | 2 | 2014 | 26 | 0.060 |
Why?
|
| Colorado | 2 | 2014 | 37 | 0.060 |
Why?
|
| Protein Isoforms | 1 | 2005 | 278 | 0.060 |
Why?
|
| Income | 1 | 2005 | 85 | 0.060 |
Why?
|
| Oncology Service, Hospital | 1 | 2004 | 6 | 0.060 |
Why?
|
| Behavior, Animal | 1 | 2007 | 381 | 0.060 |
Why?
|
| Androgens | 1 | 2005 | 175 | 0.060 |
Why?
|
| Cell-Free System | 1 | 2004 | 51 | 0.060 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2004 | 30 | 0.060 |
Why?
|
| Animals, Newborn | 1 | 2006 | 525 | 0.060 |
Why?
|
| Periodicals as Topic | 1 | 2006 | 168 | 0.060 |
Why?
|
| Colorectal Neoplasms | 2 | 2003 | 980 | 0.060 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2005 | 91 | 0.060 |
Why?
|
| Estrogens | 1 | 2005 | 200 | 0.060 |
Why?
|
| Peritoneum | 1 | 2004 | 57 | 0.060 |
Why?
|
| Health Services Research | 2 | 2014 | 138 | 0.060 |
Why?
|
| Cervix Uteri | 1 | 2004 | 71 | 0.060 |
Why?
|
| Cystadenoma, Serous | 1 | 2003 | 15 | 0.060 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2004 | 33 | 0.060 |
Why?
|
| Culture Media, Conditioned | 1 | 2004 | 103 | 0.060 |
Why?
|
| Proteomics | 1 | 2005 | 232 | 0.060 |
Why?
|
| Exercise Therapy | 1 | 2024 | 82 | 0.050 |
Why?
|
| Lung Neoplasms | 2 | 2008 | 2371 | 0.050 |
Why?
|
| Feeding Behavior | 1 | 2006 | 328 | 0.050 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2003 | 49 | 0.050 |
Why?
|
| Communication | 1 | 2006 | 462 | 0.050 |
Why?
|
| SEER Program | 1 | 2003 | 205 | 0.050 |
Why?
|
| Rats | 1 | 2009 | 4048 | 0.050 |
Why?
|
| Guidelines as Topic | 1 | 2003 | 158 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2006 | 1704 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2003 | 341 | 0.050 |
Why?
|
| Pediatrics | 2 | 1999 | 361 | 0.050 |
Why?
|
| Tape Recording | 2 | 2012 | 19 | 0.050 |
Why?
|
| Health Care Costs | 1 | 2023 | 236 | 0.050 |
Why?
|
| Musculoskeletal Diseases | 1 | 2001 | 34 | 0.050 |
Why?
|
| Rheumatology | 1 | 2001 | 35 | 0.050 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2004 | 450 | 0.050 |
Why?
|
| Linear Models | 2 | 2014 | 422 | 0.050 |
Why?
|
| Up-Regulation | 1 | 2004 | 726 | 0.050 |
Why?
|
| Women's Health Services | 1 | 2001 | 14 | 0.050 |
Why?
|
| Christianity | 1 | 2001 | 37 | 0.050 |
Why?
|
| Prostate-Specific Antigen | 1 | 2003 | 343 | 0.050 |
Why?
|
| Insurance, Health | 2 | 2015 | 164 | 0.050 |
Why?
|
| Motivation | 1 | 2023 | 296 | 0.050 |
Why?
|
| Dialysis Solutions | 1 | 2000 | 7 | 0.050 |
Why?
|
| Poverty | 2 | 2019 | 183 | 0.050 |
Why?
|
| Chylous Ascites | 1 | 2000 | 9 | 0.040 |
Why?
|
| Superior Vena Cava Syndrome | 1 | 2000 | 16 | 0.040 |
Why?
|
| Stress, Psychological | 1 | 2023 | 322 | 0.040 |
Why?
|
| Smoking | 3 | 2008 | 625 | 0.040 |
Why?
|
| Spermatozoa | 2 | 2012 | 62 | 0.040 |
Why?
|
| Public Health | 1 | 2021 | 139 | 0.040 |
Why?
|
| Peritoneal Dialysis | 1 | 2000 | 31 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2007 | 2395 | 0.040 |
Why?
|
| Opiate Substitution Treatment | 1 | 2020 | 41 | 0.040 |
Why?
|
| Photography | 1 | 2019 | 37 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2003 | 665 | 0.040 |
Why?
|
| Contraceptive Agents | 1 | 2019 | 20 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2003 | 2497 | 0.040 |
Why?
|
| Proteins | 1 | 2005 | 787 | 0.040 |
Why?
|
| Illinois | 1 | 2001 | 485 | 0.040 |
Why?
|
| Blood Pressure | 2 | 2015 | 906 | 0.040 |
Why?
|
| Testosterone | 2 | 2012 | 272 | 0.040 |
Why?
|
| Medical History Taking | 1 | 1999 | 83 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 2018 | 114 | 0.040 |
Why?
|
| Superoxides | 1 | 1998 | 74 | 0.040 |
Why?
|
| NADPH Oxidases | 1 | 1998 | 82 | 0.040 |
Why?
|
| Plethysmography, Impedance | 1 | 2017 | 4 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2012 | 855 | 0.040 |
Why?
|
| Microglia | 1 | 1998 | 108 | 0.040 |
Why?
|
| Ovariectomy | 1 | 2017 | 82 | 0.040 |
Why?
|
| Brain | 1 | 2007 | 2306 | 0.040 |
Why?
|
| Fertility Preservation | 1 | 2017 | 19 | 0.040 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2017 | 79 | 0.030 |
Why?
|
| Diet Therapy | 1 | 2016 | 20 | 0.030 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2016 | 23 | 0.030 |
Why?
|
| Women's Health | 1 | 1997 | 103 | 0.030 |
Why?
|
| Lower Extremity | 1 | 2017 | 88 | 0.030 |
Why?
|
| Seroepidemiologic Studies | 1 | 2016 | 54 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2017 | 115 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2017 | 301 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2016 | 85 | 0.030 |
Why?
|
| Thigh | 1 | 1996 | 39 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2016 | 118 | 0.030 |
Why?
|
| Perineum | 1 | 1996 | 36 | 0.030 |
Why?
|
| Developing Countries | 1 | 2016 | 80 | 0.030 |
Why?
|
| Synovitis | 2 | 2008 | 14 | 0.030 |
Why?
|
| Patient Navigation | 1 | 2015 | 14 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 376 | 0.030 |
Why?
|
| Self Report | 1 | 2017 | 297 | 0.030 |
Why?
|
| Radiotherapy | 1 | 2017 | 332 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2013 | 2018 | 0.030 |
Why?
|
| New South Wales | 1 | 2014 | 3 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 281 | 0.030 |
Why?
|
| Idaho | 1 | 2014 | 8 | 0.030 |
Why?
|
| Sex Factors | 2 | 2011 | 1075 | 0.030 |
Why?
|
| Massachusetts | 1 | 2014 | 33 | 0.030 |
Why?
|
| Organizational Case Studies | 1 | 2014 | 28 | 0.030 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1999 | 400 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2005 | 2507 | 0.030 |
Why?
|
| Global Health | 1 | 2016 | 193 | 0.030 |
Why?
|
| Pennsylvania | 1 | 2014 | 95 | 0.030 |
Why?
|
| Skin Transplantation | 1 | 1996 | 184 | 0.030 |
Why?
|
| Psychology, Child | 1 | 1994 | 12 | 0.030 |
Why?
|
| Education, Continuing | 1 | 1994 | 11 | 0.030 |
Why?
|
| Internal-External Control | 1 | 1994 | 45 | 0.030 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2013 | 24 | 0.030 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2013 | 35 | 0.030 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2013 | 33 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2014 | 304 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 596 | 0.030 |
Why?
|
| Diabetic Angiopathies | 1 | 1993 | 37 | 0.030 |
Why?
|
| DNA Repair Enzymes | 1 | 2013 | 55 | 0.030 |
Why?
|
| Leg | 1 | 2014 | 140 | 0.030 |
Why?
|
| Joint Diseases | 1 | 1993 | 49 | 0.030 |
Why?
|
| Adenosine Triphosphatases | 1 | 2013 | 155 | 0.030 |
Why?
|
| Plasmodium | 1 | 2012 | 10 | 0.030 |
Why?
|
| Hematologic Tests | 1 | 2012 | 15 | 0.030 |
Why?
|
| Blood Chemical Analysis | 1 | 2012 | 41 | 0.030 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2013 | 54 | 0.030 |
Why?
|
| Lymphoscintigraphy | 1 | 2012 | 4 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2013 | 216 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 1996 | 471 | 0.030 |
Why?
|
| California | 1 | 2012 | 146 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2012 | 303 | 0.030 |
Why?
|
| Metastasectomy | 1 | 2012 | 9 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2003 | 1747 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2013 | 494 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 983 | 0.020 |
Why?
|
| Interinstitutional Relations | 1 | 2011 | 29 | 0.020 |
Why?
|
| Diabetes Complications | 2 | 2007 | 171 | 0.020 |
Why?
|
| Systems Integration | 1 | 2011 | 36 | 0.020 |
Why?
|
| Hypercholesterolemia | 1 | 1991 | 159 | 0.020 |
Why?
|
| Ultrasonography | 2 | 2004 | 719 | 0.020 |
Why?
|
| Salamandridae | 1 | 2010 | 2 | 0.020 |
Why?
|
| Erythrocyte Count | 1 | 2010 | 22 | 0.020 |
Why?
|
| Soil | 1 | 2010 | 46 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2013 | 543 | 0.020 |
Why?
|
| Pneumonectomy | 1 | 2012 | 211 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2011 | 179 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 848 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2010 | 193 | 0.020 |
Why?
|
| Erythrocytes | 1 | 2010 | 254 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2009 | 94 | 0.020 |
Why?
|
| Rabbits | 1 | 2009 | 640 | 0.020 |
Why?
|
| Methylmercury Compounds | 1 | 1988 | 3 | 0.020 |
Why?
|
| Fish Products | 1 | 1988 | 3 | 0.020 |
Why?
|
| Toes | 1 | 2007 | 14 | 0.020 |
Why?
|
| Mathematics | 1 | 1988 | 191 | 0.020 |
Why?
|
| Nursing Methodology Research | 1 | 2007 | 11 | 0.020 |
Why?
|
| Hematology | 1 | 2008 | 30 | 0.020 |
Why?
|
| Helping Behavior | 1 | 2007 | 8 | 0.020 |
Why?
|
| Medical Staff | 1 | 2007 | 10 | 0.020 |
Why?
|
| Nursing Assessment | 1 | 2007 | 20 | 0.020 |
Why?
|
| Nursing Staff | 1 | 2007 | 10 | 0.020 |
Why?
|
| Color | 1 | 2008 | 85 | 0.020 |
Why?
|
| Chromatography, Gas | 1 | 2007 | 28 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2013 | 1243 | 0.020 |
Why?
|
| Nutritional Status | 1 | 2007 | 81 | 0.020 |
Why?
|
| Liver | 1 | 2012 | 1211 | 0.020 |
Why?
|
| Medically Underserved Area | 1 | 2007 | 27 | 0.020 |
Why?
|
| Nurse Practitioners | 1 | 2007 | 30 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2010 | 385 | 0.020 |
Why?
|
| Nevus, Pigmented | 1 | 2007 | 52 | 0.020 |
Why?
|
| Individuality | 1 | 1988 | 110 | 0.020 |
Why?
|
| Fingers | 1 | 2007 | 69 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2008 | 315 | 0.020 |
Why?
|
| Self-Help Groups | 1 | 2007 | 14 | 0.020 |
Why?
|
| Research Design | 1 | 2011 | 591 | 0.020 |
Why?
|
| Diabetic Nephropathies | 2 | 2000 | 87 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2008 | 230 | 0.020 |
Why?
|
| Remission Induction | 1 | 2008 | 741 | 0.020 |
Why?
|
| Songbirds | 1 | 2007 | 84 | 0.020 |
Why?
|
| Minority Groups | 1 | 2007 | 147 | 0.020 |
Why?
|
| Leadership | 1 | 2007 | 141 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2005 | 27 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 1988 | 899 | 0.020 |
Why?
|
| Chromatography, Affinity | 1 | 2005 | 81 | 0.020 |
Why?
|
| Methoxychlor | 1 | 2005 | 1 | 0.020 |
Why?
|
| Water Supply | 1 | 1985 | 61 | 0.020 |
Why?
|
| Leukemia Inhibitory Factor | 1 | 2005 | 4 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2006 | 97 | 0.020 |
Why?
|
| Motor Activity | 1 | 2007 | 327 | 0.020 |
Why?
|
| Lipase | 1 | 2005 | 21 | 0.020 |
Why?
|
| Neural Conduction | 1 | 2005 | 71 | 0.020 |
Why?
|
| S100 Proteins | 1 | 2004 | 52 | 0.010 |
Why?
|
| Placebos | 1 | 2005 | 211 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 2004 | 222 | 0.010 |
Why?
|
| Reference Values | 1 | 2005 | 662 | 0.010 |
Why?
|
| Seasons | 1 | 1985 | 240 | 0.010 |
Why?
|
| Carboplatin | 1 | 2005 | 312 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2005 | 264 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2005 | 463 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 1606 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2005 | 474 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2006 | 467 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 1985 | 275 | 0.010 |
Why?
|
| Tenosynovitis | 1 | 2001 | 7 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2014 | 8300 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2005 | 2064 | 0.010 |
Why?
|
| Cytokines | 1 | 2005 | 811 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2005 | 3024 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2005 | 1715 | 0.010 |
Why?
|
| Age Distribution | 1 | 2001 | 199 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2001 | 186 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2004 | 693 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2007 | 2327 | 0.010 |
Why?
|
| Cyclic N-Oxides | 1 | 1998 | 33 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 1998 | 68 | 0.010 |
Why?
|
| Free Radicals | 1 | 1998 | 71 | 0.010 |
Why?
|
| Sheep | 1 | 1998 | 251 | 0.010 |
Why?
|
| Body Constitution | 1 | 1997 | 26 | 0.010 |
Why?
|
| Cattle | 1 | 1998 | 378 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 2000 | 414 | 0.010 |
Why?
|
| Waiting Lists | 1 | 1997 | 187 | 0.010 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 1998 | 319 | 0.010 |
Why?
|
| Vagina | 1 | 1996 | 177 | 0.010 |
Why?
|
| Curriculum | 1 | 1999 | 572 | 0.010 |
Why?
|
| Albuminuria | 1 | 1993 | 48 | 0.010 |
Why?
|
| Diffusion of Innovation | 1 | 1994 | 72 | 0.010 |
Why?
|
| Surgical Flaps | 1 | 1996 | 250 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1998 | 2887 | 0.010 |
Why?
|
| Diabetic Retinopathy | 1 | 1993 | 91 | 0.010 |
Why?
|
| Research | 1 | 1994 | 251 | 0.010 |
Why?
|